Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.

Eudocia Quant LeeAlona MuzikanskyDan G DudaSarah GaffeyJorg DietrichLakshmi NayakUgonma N ChukwuekeRameen BeroukhimLisa DohertyCaroline Kane LaubDebra LaFrankieBrittney FontanaJennifer StefanikSandra RulandVictoria CarusoJennifer BrunoKeith LigonDavid A ReardonPatrick Y Wen

Published in: Cancer medicine (2019)

Ponatinib was associated with minimal activity in bevacizumab-refractory GBM patients. Circulating biomarker data confirmed pharmacodynamic changes and suggested that resistance to ponatinib may be related to an increase in inflammatory cytokines.

Keyphrases

end stage renal disease
ejection fraction
chronic myeloid leukemia
newly diagnosed
chronic kidney disease
metastatic colorectal cancer
electronic health record
clinical trial
machine learning
patient reported